search
Back to results

Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation

Primary Purpose

Chronic Obstructive Pulmonary Disease, Sepsis, Antibiotics

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
ciprofloxacin
trimethoprim-sulfamethoxazole
Sponsored by
University of Monastir
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring chronic obstructive pulmonary disease, pulmonary infection, antibiotic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation.
  • The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas criteria (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30.

Exclusion Criteria:

  • Pneumonia documented with chest radiography
  • Antibiotic treatment in the ten previous days of ICU admission
  • Former inclusion in the study
  • History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole
  • Pregnancy or breast feeding
  • Severe chronic disease: heart, liver, kidney.
  • Known immunodeficiency (malignant hemopathy, AIDS...)
  • Digestive disease which could affect the absorption of the drugs
  • Concomitant infection which requires systemic antibiotic treatment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Ciprofloxacin

    trimethoprim-sulfamethoxazole

    Arm Description

    750 mg a day during 10 days

    2000 mg a day for 10 days

    Outcomes

    Primary Outcome Measures

    Two major criteria will be used for the determination of sample size and the estimate of the effectiveness of the treatments of the study: 1. mortality (in ICU and in the hospital) 2. rate of additional antibiotherapy course.
    The decision to initiate new antibiotics was left to the discretion of the treating physician, and if resistant species were cultured, the protocol treatment was not systematically changed unless the clinical course of the patient worsened

    Secondary Outcome Measures

    Mechanical ventilation duration
    duration of mechanical ventilation
    Duration of hospital stay
    duration of hospital stay

    Full Information

    First Posted
    November 12, 2008
    Last Updated
    February 20, 2020
    Sponsor
    University of Monastir
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00791505
    Brief Title
    Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
    Official Title
    Antibiotic Comparison Exacerbation COPD
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2002 (undefined)
    Primary Completion Date
    June 2005 (Actual)
    Study Completion Date
    June 2005 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Monastir

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Although the use of antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is largely accepted, controversy remains regarding whether the choice of antibiotic has any impact on outcome. Our aim was to compare the effects of the combination of trimethoprim and sulfamethoxazole and ciprofloxacin in patients treated for severe COPD exacerbation requiring mechanical ventilation.
    Detailed Description
    Antibiotic therapy has been shown to be beneficial in patients with severe acute exacerbation of chronic obstructive pulmonary disease (COPD). Although recent guidelines support the use of new antibiotics there is no evidence that newer antibiotics are any better than older agents. The choice of antibiotic to be used in this situation is challenging to the clinician who must choose between traditional antibiotics (cyclins, aminopénicillins, cotrimoxazole...) and new antimicrobial agents. Indeed, available comparative studies did not show an obvious superiority of new antibiotics compared to their predecessors . Taking into account bacterial agents associated to COPD exacerbations, one must choose an antibiotic which has the best activity against Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis. News quinolones are represented as an interesting alternative to standard antibiotics because of their large spectrum of action and of their pharmacokinetic advantages allowing high tissue penetration in the pulmonary parenchyma and tracheobronchial tree. Data on their use among patients having moderate exacerbation of COPD are encouraging but their effectiveness in more severe presentations is not established. The objective of this randomized controlled and double blind study is to evaluate the effectiveness and tolerance of ciprofloxacin compared to trimethoprim sulfamethoxazole in patients admitted to ICU for severe exacerbation of COPD requiring mechanical ventilation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Obstructive Pulmonary Disease, Sepsis, Antibiotics
    Keywords
    chronic obstructive pulmonary disease, pulmonary infection, antibiotic

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    170 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Ciprofloxacin
    Arm Type
    Active Comparator
    Arm Description
    750 mg a day during 10 days
    Arm Title
    trimethoprim-sulfamethoxazole
    Arm Type
    Active Comparator
    Arm Description
    2000 mg a day for 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    ciprofloxacin
    Other Intervention Name(s)
    fluoroquinolone
    Intervention Description
    1500 mg a day for 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    trimethoprim-sulfamethoxazole
    Other Intervention Name(s)
    sulfatrim, bactrim
    Intervention Description
    2000 mg a day for 10 days
    Primary Outcome Measure Information:
    Title
    Two major criteria will be used for the determination of sample size and the estimate of the effectiveness of the treatments of the study: 1. mortality (in ICU and in the hospital) 2. rate of additional antibiotherapy course.
    Description
    The decision to initiate new antibiotics was left to the discretion of the treating physician, and if resistant species were cultured, the protocol treatment was not systematically changed unless the clinical course of the patient worsened
    Time Frame
    30 day after starting protocol
    Secondary Outcome Measure Information:
    Title
    Mechanical ventilation duration
    Description
    duration of mechanical ventilation
    Time Frame
    30 days after starting protocol
    Title
    Duration of hospital stay
    Description
    duration of hospital stay
    Time Frame
    30 days after starting protocol

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All patients having a COPD (according to the definition of the American Thoracic Society) and having an acute exacerbation leading to an acute respiratory failure requiring the admission to ICU and mechanical ventilation. The acute exacerbation of COPD is defined by increase in the frequency of cough, the volume and the purulence of expectoration and increase of baseline dyspnea. To be included, patients must have respiratory rate >30 cycles/min and one of the following blood gas criteria (with blood gases performed right before the initiation of mechanical ventilation): PaC02 > 6kPa and arterial pH <7.30. Exclusion Criteria: Pneumonia documented with chest radiography Antibiotic treatment in the ten previous days of ICU admission Former inclusion in the study History of allergy to the quinolones and/or to trimethoprim sulfamethoxazole Pregnancy or breast feeding Severe chronic disease: heart, liver, kidney. Known immunodeficiency (malignant hemopathy, AIDS...) Digestive disease which could affect the absorption of the drugs Concomitant infection which requires systemic antibiotic treatment
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    nouira semir, MD
    Organizational Affiliation
    research unit 04/UR/08-20
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    20536364
    Citation
    Nouira S, Marghli S, Besbes L, Boukef R, Daami M, Nciri N, Elatrous S, Abroug F. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis. 2010 Jul 15;51(2):143-9. doi: 10.1086/653527.
    Results Reference
    derived

    Learn more about this trial

    Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation

    We'll reach out to this number within 24 hrs